Follow Us:
Through structured in‑licensing and commercialisation arrangements, Smartway supports regulatory approval, including marketing authorisation, market entry and ongoing supply across the UK and selected international markets.
Our approach is designed for products that require more than distribution alone - combining regulatory capability, commercial infrastructure and operational execution to deliver sustainable access.
We work with pharmaceutical manufacturers, product owners and developers who are seeking:
We partner with established pharmaceutical companies seeking disciplined regional expansion, as well as product owners with late-stage or under-commercialised assets that require structured regulatory strategy and integrated commercial delivery.
Smartway provides an integrated approach to market access and commercialisation, tailored to the needs of each product and partner.
We enter into structured inward licensing arrangements for products aligned with Smartway’s therapeutic focus, regulatory expertise and supply capabilities. Each opportunity is assessed for regulatory feasibility, commercial sustainability and long-term supply resilience. Smartway pursues opportunities aligned with defined therapeutic focus areas and long-term portfolio strategy.
Smartway has structured and executed inward licensing arrangements within regulated markets, including shared regulatory investment, MHRA-led approval and MAH-based commercialisation, supporting products through approval and long-term commercial supply.
Smartway supports regulatory strategy and execution, including dossier development, remediation and submission, as well as ongoing regulatory maintenance. We work closely with partners and regulatory authorities to support approval and continued compliance throughout the product lifecycle.
Approved products are supported through licensed manufacture and supply arrangements, underpinned by Smartway’s established national distribution infrastructure serving community pharmacy, hospital systems, specialist prescribers and private healthcare providers across the UK and selected European and international markets.
Beyond initial launch, Smartway provides ongoing commercial, regulatory and supply chain management to support sustainable access, continuity of supply and long‑term portfolio value.
While Smartway supports early access and unlicensed supply where clinically appropriate, our market access and commercialisation activities are focused on transitioning products into licensed, sustainable supply.
This approach supports continuity of access for patients and healthcare professionals, while providing partners with a clear and proportionate route to long‑term commercialisation.
Smartway combines regulatory expertise with established commercial and distribution infrastructure, allowing partners to progress from approval to routine supply without fragmentation or unnecessary hand-offs.
"We approach licensed products as long-term portfolio assets, not short-term transactions. We invest alongside our partners in regulatory conversion and MAH-led commercialisation to ensure products move into sustained, compliant routine supply within the healthcare system." - Josh Cocklin, Chief Executive
Unlike pure regulatory service providers or standalone distributors, Smartway integrates regulatory execution with established supply pathways, enabling a seamless transition from approval to routine commercial supply.
Smartway uniquely combines regulatory execution, inward licensing capability and established national distribution infrastructure serving community pharmacy, hospital systems, specialist prescribers and private healthcare providers, within a single integrated platform.
For decades, Smartway has supplied medicines across community pharmacy, hospital systems, specialist prescribers and private healthcare settings. This established and embedded operational presence, supported by national distribution capability and export activity, provides partners with direct access to routine, compliant supply pathways within the UK healthcare system and selected international markets.
This embedded operational presence is supported by established compliance systems, pharmacovigilance oversight and quality governance frameworks aligned with UK regulatory expectations, providing partners with confidence in both regulatory stewardship and commercial execution.
Our experience across early access programmes, licensed distribution and international supply enables a joined-up approach to market entry in complex and constrained environments, supporting both regulatory confidence and commercial delivery.
Typical engagement models
Smartway structures partnerships to reflect the regulatory status, maturity and commercial objectives of each product. Typical models include:
In‑licensing and commercialisation partnerships
Structured inward licensing arrangements where Smartway supports regulatory approval, commercial launch and long‑term licensed supply within defined territories.
MAH‑led market entry and lifecycle management
Support for regulatory approval for marketing authorisations and ongoing maintenance, combined with integrated commercial supply and distribution across hospital and pharmacy settings.
Transition from early access to licensed supply
Planning and execution of the pathway from unlicensed or early access supply into routine, licensed commercial distribution, supporting continuity of access.
Regional or portfolio expansion partnerships
Selective territory commercialisation for established products, providing regulatory and commercial infrastructure without the need for in‑country build‑out.
Initiate a strategic discussion
Market access and product commercialisation is a core strategic function within Smartway. We engage selectively with partners seeking structured, long-term entry into the UK and regulated international markets.
To discuss a potential licensing or commercialisation opportunity, please Contact Us to arrange a confidential conversation.